The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Abstract
Background Hereditary breast cancer has been associated with mutations in the BRCA1 and BRCA2 genes and has a natural history different from sporadic breast cancer. We investigated disease-free and overall survival for patients with a proven BRCA1 alteration.Methods We estimated disease-free and overall survival for 49 Dutch patients from 19 consecutive families with a proven specific BRCA1 mutation and one family with strong evidence for linkage to the BRCA1 gene. We compared clinical outcome and data on tumour size, histology, axillary nodal status, contralateral breast cancer, and oestrogen-receptor and progesterone-receptor status with those of 196 patients with sporadic breast cancer, matched for age and year of diagnosis.Findings Disease-free survival for BRCA1 and sporadic patients at 5 years was 49% (95% CI 33-64) and 51% (43-59), respectively (p=0.98). Overall survival at 5 years was 63% (47-76) and 69% (62-76), respectively (p=0.88). Recurrence and death rates did not differ significantly between groups. Hazard ratios for recurrence and death among BRCA1 patients were 1.00 (0.65-1.55) and 1.04 (0.63-1.71) relative to sporadic patients (p=0.88), and these did not differ significantly after adjustment for prognostic factors. Patients with BRCA1-associated breast cancer had twice as many progesterone-receptor-negative tumours (p<0.005) and development of contralateral breast cancer was four to five times as frequent as in the sporadic group (p<0.001).Interpretation We showed that disease-free and overall survival were similar for sporadic and hereditary breast cancer in the presence of different tumour characteristics, which has implications for screening prophylactic therapy, and different treatments of hereditary breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BRCA2 mutation carriers, on the contrary, present tumours with pathologic features similar to those of sporadic tumours [2-10].”
From Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature (2010) · cites this paper as [6]
In the citing paper
“Several studies suggest that BRCA gene mutation might influence response to radiation therapy because tumours in BRCA1/BRCA2 carriers are more sensitive to ionising radiation [5-12].”
From Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature (2010) · cites this paper as [6]
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J., Lee, M. K., Newman, B. M., Morrow, J. E., Anderson, L. A., Huey, B., & King, M. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,544
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
The statistical analysis of failure time data
Herson, J. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90009-x · Cited by 1,391
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
Age as prognostic factor in premenopausal breast carcinoma
de la Rochefordière, A., Campana, F., Fenton, J., Vilcoq, J. R., Fourquet, A., Asselain, B. J. R., Scholl, S. M., Pouillart, P., Durand, J., & Magdelénat, H. (1993) · The Lancet · doi:10.1016/0140-6736(93)92407-k · Cited by 481
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients
Petrij-Bosch, A., Peelen, T., van Vliet, M., van Eijk, R., Olmer, R., Drüsedau, M., Hogervorst, F. B. L., Hageman, S., Arts, P. J. W., Ligtenberg, M. J. L., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-341 · Cited by 432
Self-citationTumour biological features of BRCA1-induced breast and ovarian cancer
Johannsson, O. T., Idvall, I., Anderson, C., Borg, Å., Barkardottir, R. B., Egilsson, V., & Olsson, H. L. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)89007-7 · Cited by 344
Research works printed but not linked: 3
- Lynch, 1993, Increased proliferation in hereditary breast cancer, Proc ASCO, 12, 82
- Lynch, 1994, Distinctive clinicopathological features of BRCA1 linked hereditary breast cancer, Proc ASCO, 13, 56
- Solin, 1996, Breast cancer in young women: the University of Pennsylvania experience—breast cancer: advances in biology and therapeutics, John Libbey Eurotext, 351
Cited by
Sorted by citations
Items 401–450 of 450
Familiäres Mammakarzinom — Beratung und Betreuung betroffener Familien
Runnebaum, I. B., & Emmerich, D. (2002) · Springer eBooks · doi:10.1007/978-3-662-08460-1_4
Stellenwert molekularbiologischer Verfahren in der klinischen Hämatologie und Onkologie
Maschmeyer, G., & Dörken, B. (2001) · Springer eBooks · doi:10.1007/978-3-642-56818-3_19
Wong, J. S., & Garber, J. E. (2001) · Familial Cancer · doi:10.1023/a:1013844807960
The Analysis of Novel Gene Targets in Breast Cancer in Women ≤35 years
Lambe, S. M. (2008) · Figshare
CHEK2 1100delC and polygenic susceptibility to breast cancer and colorectal cancer
Wasielewski, M. (2009) · RePub (Erasmus University Rotterdam)
Genetic Screening and Counseling for High-Risk Populations
Daly, M. (2006) · Springer eBooks · doi:10.1007/0-387-31056-8_25
Epidemiology and Clinical Risk Factors
Daly, M. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-161-9_1
Risk Reduction Strategies: Surgical Perspective
Spiguel, L. R., & Hansen, N. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5891-3_8
Genetic changes in breast cancer. What do they mean?
Dervan, P. A. (1998) · Current Diagnostic Pathology · doi:10.1016/s0968-6053(98)80002-1
El-Amm, J., Ghanem, H., Zeck, J. C., Akin, E. A., & Siegel, R. (2012) · Clinical Breast Cancer · doi:10.1016/j.clbc.2012.05.002
Surgical Management of Inherited Susceptibility to Breast Cancer
Freisinger, F., & Domchek, S. M. (2009) · Springer eBooks · doi:10.1007/978-0-387-87583-5_4
La prévention du cancer du sein par mammectomie prophylactique
Lefranc, J., Brémond, A., & Dauplat, J. (1998) · Chirurgie · doi:10.1016/s0001-4001(98)80015-9
Considerations in genetic counseling for inherited breast cancer predisposition
Robson, M. E., & Offit, K. (2002) · Seminars in Radiation Oncology · doi:10.1053/srao.2002.35255
The Optimization of Breast Conservation
Dooley, W. C., Keshtgar, M., Tot, T., Yamamoto, D., & El-Tamer, M. B. (2011) · International Journal of Breast Cancer · doi:10.4061/2011/456378
Update on chemoprevention in BRCA1 and BRCA2 mutation carriers
Stumacher, M., & Domchek, S. M. (2005) · Breast Cancer Online · doi:10.1017/s1470903105002890
Testing for Hereditary Risk of Breast and Ovarian Cancer
Frank, T. S. (2000) · Public Health Genomics · doi:10.1159/000051138
Benefits and Costs of Genetic Screening for Breast Cancer
Grann, V. R., & Jacobson, J. S. (2000) · Public Health Genomics · doi:10.1159/000051137
Risque génétique de cancer du sein et de l'ovaire
Eisinger, F. (1998) · Chirurgie · doi:10.1016/s0001-4001(98)80013-5
The Psychosocial Impact of Prophylactic Mastectomy and Salpingo-Oophorectomy
Bresser, P. J. C. (2009) · RePub (Erasmus University Rotterdam)
Safety of breast conservation therapy in BRCA1 and BRCA2 cancers
Alpert, T. E., & Haffty, B. G. (2004) · Breast Cancer Online · doi:10.1017/s1470903104001981
Frank, T. S., Deffenbaugh, A. M., Hulick, M., & Gumpper, K. (1999) · Disease Markers · doi:10.1016/s0029-7844(99)90066-2 · Cited by 15
Trombetta, M. G., Kotinsley, K., & Julian, T. B. (2011) · Journal of Radiotherapy in Practice · doi:10.1017/s1460396911000021
BRCA1 and BRCA2 Cancer Syndromes and Clinical Significance
Gao, F. F., & Dabbs, D. J. (2014) · Pathology Case Reviews · doi:10.1097/pcr.0000000000000021
Bryant, E. M., James, A. G., Solove, R. J., Engstrom, P. F., Farrell, C. D., Garber, J. E., Gruber, S. B., Daly, M. B., Angelos, P., Lurie, R. H., et al. (2002)
Effektivität der bilateralen mastektomie bei frauen mit familiärer brustkrebsanamnese
Gerber, B., & Friese, K. (1999) · Strahlentherapie und Onkologie · doi:10.1007/bf02743585
Molekulare Grundlagen des sporadischen Mammakarzinoms
Kuschel, B., & Beckmann, M. W. (2002) · Springer eBooks · doi:10.1007/978-3-642-56297-6_3
Carracedo, A. (2011) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Susceptibility genes in hereditary breast cancer
Vahteristo, P. (2003) · Työväentutkimus Vuosikirja
Occult cancer: suspected breast and BRCA gene mutations
Hutton, M. L., Voian, N. C., & Farrell, C. D. (2013) · Community Oncology · doi:10.12788/j.cmonc.0018
Clinical studies in breast cancer: improving cure and care
Cocquyt, V. (2003) · Ghent University Academic Bibliography (Ghent University)
Mariño, M. A. G. (2018) · Revista de Salud Pública · doi:10.15446/rsap.v20n2.64866
Chompret, A. (2003) · Imagerie de la Femme · doi:10.1016/s1776-9817(05)80643-1 · Cited by 4
Brekelmans, C. T. M., Seynaeve, C., Menke, M. N., & van den Ouweland, A. (2001)
Self-citationClinical Implementation of Translational Genomics
Chung, W. K. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-369420-1.00030-5
Histopathological Findings in Prophylactic Surgical Specimens
Dılek, F. H., & Kahraman, D. İ. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-66853-2_26
Breast Cancer Risk-reducing Strategies in BRCA1/2 Mutation Carriers
Heemskerk‐Gerritsen, B. A. M. (2014) · EUR Research Repository (Erasmus University Rotterdam)
(2009) · Wiley eBooks · doi:10.1002/9781444306361.ch13
Port, E. R., & Cody, H. S. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5221-0.00081-4
OCDE (2001) · OECD eBooks · doi:10.1787/9789264288577-fr
Batalini, F., Xiong, N., Tayob, N., Polak, M. M., Eismann, J., Cantley, L. C., Shapiro, G. I., Adalsteinsson, V. A., Winer, E. P., Konstantinopoulos, P. A., et al. (2023) · doi:10.1158/1078-0432.c.6532290.v1
Medullary breast cancer and germline BRCA1 mutations: a possible criterion for genetic testing
Apostol, A. I., Lim, D. W., & Narod, S. A. (2025) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-025-00321-y
Sarantaus, L. (2002) · Työväentutkimus Vuosikirja
Update Mammakarzinom 2024 Teil 2 – Patientinnen mit Frühstadien des Mammakarzinoms
Janni, W., Kolberg, H.-C., Hartkopf, A. D., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Jackisch, C., Marme, F., et al. (2025) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-2661-0366
Bayrakçı, İ., Coşar, R., Süt, N., Gürkan, H., Çetinkaya, Ö. F., Şenödeyici, E., Divriklioğlu, D., Kahveci, G. B., Küçükarda, A., Hacıoğlu, M. B., et al. (2026) · Cancers · doi:10.3390/cancers18193073
Tinterri, C., Grimaldi, S. D. M., Sagona, A., Barbieri, E., Darwish, S. S., Bottini, A., Canavese, G., & Gentile, D. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.10246151
Nithin, S. G., Roy, P. G., Pramanik, R., Batra, A., Kataria, K., Mishra, A., Deo, S. V. S., Saini, S. K., Sharma, D. N., Mathur, S., et al. (2026) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_145_26
Hereditärer Brust- und Eierstockkrebs
Wagner, T. M. U., Langbauer, G., Möslinger, R., Schreiber, M., Fleischmann, E., Kubista, E., Muhr, D., Hareter, M., Lachner, I., & Kofler, P. (2001) · Springer eBooks · doi:10.1007/978-3-642-56889-3_8
Wagner, T., Langbauer, G., Fleischmann, E., & Kubista, E. (1999) · Onkologie heute · doi:10.1007/978-3-7091-6402-0_2
Metadata
- Authors
- Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., Devilee, P., Meijers-Heijboer, E., & Klijn, J.
- Affiliations
- Academisch Ziekenhuis Rotterdam (NL)
- Erasmus University Rotterdam (NL)
- Leiden University (NL)
- Corresponding author
- Klijn, JGM
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1998-01
- Volume
- 351
- Issue
- 9099
- Pages
- 316-321
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2137086763
- Cited by
- 452
- References
- 31
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 3 · 2023: 7 · 2022: 1 · 2021: 7 · 2020: 8 · 2019: 7 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 13 · 2014: 10 · 2013: 7 · 2012: 5
- FWCI
- 28.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- KWF Kankerbestrijding
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- hereditary breast cancer, BRCA1 mutation, sporadic breast cancer, disease-free survival, overall survival, contralateral breast cancer, estrogen receptor status, tumor characteristics, tumor recurrence, breast cancer screening
- MeSH terms
- Adult, Aged, Breast Neoplasms, Female, Humans, Middle Aged, Prognosis, Risk, Odds Ratio, Survival Analysis, Germ-Line Mutation, Disease-Free Survival, Genes, BRCA1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
